Novavax, Inc. (NASDAQ:NVAX) has a beta value of 1.61 and has seen 0.46 million shares traded in the recent trading session. The company, currently valued at $622.75M, closed the recent trade at $4.45 per share which meant it gained $0.03 on the day or 0.67% during that session. The NVAX stock price is -155.28% off its 52-week high price of $11.36 and 20.67% above the 52-week low of $3.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.93 million shares traded. The 3-month trading volume is 8.08 million shares.
Novavax, Inc. (NASDAQ:NVAX) trade information
Sporting 0.67% in the green today, the stock has traded in the red over the last five days, when the NVAX stock price touched $4.45 or saw a rise of 7.48%. Year-to-date, Novavax, Inc. shares have moved -7.30%, while the 5-day performance has seen it change -4.31%. Over the past 30 days, the shares of Novavax, Inc. (NASDAQ:NVAX) have changed -20.68%. Short interest in the company has seen 48.13 million shares shorted with days to cover at 4.04.
Novavax, Inc. (NVAX) estimates and forecasts
Figures show that Novavax, Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -37.59% over the past 6 months, with this year growth rate of 83.73%, compared to 13.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 72.10% and -277.60% for the next quarter. Revenue growth from the last financial year stood is estimated to be -13.60%.
4 analysts offering their estimates for the company have set an average revenue estimate of $101.45 million for the current quarter. 4 have an estimated revenue figure of $76.65 million for the next quarter concluding in Jun 2024.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.55% over the past 5 years.
NVAX Dividends
Novavax, Inc. is expected to release its next earnings report between May 07 and May 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Novavax, Inc. (NASDAQ:NVAX)’s Major holders
Insiders own 4.99% of the company shares, while shares held by institutions stand at 56.31% with a share float percentage of 59.27%. Investors are also buoyed by the number of investors in a company, with Novavax, Inc. having a total of 278 institutions that hold shares in the company. The top two institutional holders are State Street Corporation with over 11.68 million shares worth more than $86.78 million. As of Jun 29, 2023, State Street Corporation held 12.37% of shares outstanding.
The other major institutional holder is Vanguard Group Inc, with the holding of over 10.57 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $78.55 million and represent 11.20% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Aug 30, 2023, the former fund manager holds about 9.94% shares in the company for having 9.38 million shares of worth $75.07 million while later fund manager owns 2.64 million shares of worth $19.6 million as of Jun 29, 2023, which makes it owner of about 2.79% of company’s outstanding stock.
